TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Type
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Growing incidences and prevalence of Cancer and rare disorders
4.2.2 Increasing approval for Gene therapy Products
4.2.3 Favourable government Support for gene therapy
4.3 RESTRAINTS
4.3.1 Clinical Trial Failure associated with gene therapy
4.3.2 Challenges associated with gene therapy delivery
4.4 OPPORTUNITY
4.4.1 Growing investment in the field of gene therapy
4.4.2 Ongoing Clinical Trials Associated with Gene therapy
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENE THERAPY MARKET
6 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE
6.1 OVERVIEW
6.2 VIRAL VECTOR
6.2.1 Lentiviral Vectors (LVVs)
6.2.2 retrovirus Vectors
6.2.3 adenoviral Vectors (AdVs)
6.2.4 Adeno-associated Viral Vectors (AAVs)
6.3 NON-VIRAL VECTOR
6.3.1 physical Vector
6.3.2 chemical Vector
7 GLOBAL GENE THERAPY MARKET, BY GENE TYPE
7.1 OVERVIEW
7.2 ANTIGEN
7.3 CYTOKINE
7.4 TUMOR SUPPRESSOR
7.5 SUICIDE
7.6 DEFICIENCY
7.7 GROWTH FACTORS
7.8 RECEPTORS
7.9 OTHERS
8 GLOBAL GENE THERAPY MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 ONCOLOGICAL DISORDERS
8.3 RARE DISEASES
8.4 CARDIOVASCULAR DISEASES
8.5 NEUROLOGICAL DISORDERS
8.6 INFECTIOUS DISEASES
8.7 OTHERS
9 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD
9.1 OVERVIEW
9.2 IN VIVO GENE THERAPY
9.3 EX VIVO GENE THERAPY
10 GLOBAL GENE THERAPY MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 Canada
10.3 EUROPE
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 ASIA-PACIFIC
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5 REST OF THE WORLD
10.5.1 Middle East & Africa
10.5.2 South America
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 Product Approval/ Product Launch
11.6.2 Acquisition/ expansion
11.6.3 agreement/partnership/collaboration
12 COMPANY PROFILES
12.1 BRISTOL-MYERS SQUIBB COMPANY
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 productS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 LONZA
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCT OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 UNIQURE N.V.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 BLUEBIRD BIO, INC.
12.4.1 COMPANY OVERVIEW
12.4.2 PRODUCTS OFFERED
12.4.3 KEY DEVELOPMENTS
12.4.4 KEY STRATEGIES
12.5 ORCHARD THERAPEUTICS PLC
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 GENSIGHT BIOLOGICS
12.6.1 COMPANY OVERVIEW
12.6.2 PRODUCTS OFFERED
12.6.3 KEY DEVELOPMENTS
12.6.4 KEY STRATEGIES
12.7 NOVARTIS AG
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 AMGEN INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 SAREPTA THERAPEUTICS INC.
12.9.1 COMPANY OVERVIEw
12.9.2 FINANCIAL OVERVIEW
12.9.3 Product OFFERed
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 SPARK THERAPEUTICS, INC.
12.10.1 COMPANY OVERVIEW
12.10.1 FINANCIAL OVERVIEW
12.10.2 PRODUCTS OFFERED
12.10.3 KEY DEVELOPMENTS
12.10.4 KEY STRATEGIES
12.11 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 3 GLOBAL GENE THERAPY MARKET, FOR VIRAL VECTOR, BY REGION, 2019–2032 (USD MILLION)
TABLE 4 GLOBAL GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 5 GLOBAL GENE THERAPY MARKET, FOR LENTIVIRAL VECTORS (LVVS), BY REGION, 2019–2032 (USD MILLION)
TABLE 6 GLOBAL GENE THERAPY MARKET, FOR RETROVIRUS VECTORS, BY REGION, 2019–2032 (USD MILLION)
TABLE 7 GLOBAL GENE THERAPY MARKET, FOR ADENOVIRAL VECTORS (ADVS), BY REGION, 2019–2032 (USD MILLION)
TABLE 8 GLOBAL GENE THERAPY MARKET, FOR ADENO-ASSOCIATED VIRAL VECTORS (AAVS), BY REGION, 2019–2032 (USD MILLION)
TABLE 9 GLOBAL GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY REGION, 2019–2032 (USD MILLION)
TABLE 10 GLOBAL GENE THERAPY MARKET, FOR NON- VIRAL VECTORS, BY TYPE, 2019–2032 (USD MILLION)
TABLE 11 GLOBAL GENE THERAPY MARKET, FOR PHYSICAL VECTOR, BY REGION, 2019–2032 (USD MILLION)
TABLE 12 GLOBAL GENE THERAPY MARKET, FOR CHEMICAL VECTOR, BY REGION, 2019–2032 (USD MILLION)
TABLE 13 GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 14 GLOBAL GENE THERAPY MARKET, FOR ANTIGEN, BY REGION, 2019–2032 (USD MILLION)
TABLE 15 GLOBAL GENE THERAPY MARKET, FOR CYTOKINE, BY REGION, 2019–2032 (USD MILLION)
TABLE 16 GLOBAL GENE THERAPY MARKET, FOR TUMOR SUPPRESSOR, BY REGION, 2019–2032 (USD MILLION)
TABLE 17 GLOBAL GENE THERAPY MARKET, FOR SUICIDE, BY REGION, 2019–2032 (USD MILLION)
TABLE 18 GLOBAL GENE THERAPY MARKET, FOR DEFICIENCY, BY REGION, 2019–2032 (USD MILLION)
TABLE 19 GLOBAL GENE THERAPY MARKET, FOR GROWTH FACTORS, BY REGION, 2019–2032 (USD MILLION)
TABLE 20 GLOBAL GENE THERAPY MARKET, FOR RECEPTORS, BY REGION, 2019–2032 (USD MILLION)
TABLE 21 GLOBAL GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION)
TABLE 22 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 23 GLOBAL GENE THERAPY MARKET, FOR ONCOLOGICAL DISORDERS, BY REGION, 2019–2032 (USD MILLION)
TABLE 24 GLOBAL GENE THERAPY MARKET, FOR RARE DISEASES, BY REGION, 2019–2032 (USD MILLION)
TABLE 25 GLOBAL GENE THERAPY MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2032 (USD MILLION)
TABLE 26 GLOBAL GENE THERAPY MARKET, FOR NEUROLOGICAL DISORDERS, BY REGION, 2019–2032 (USD MILLION)
TABLE 27 GLOBAL GENE THERAPY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2032 (USD MILLION)
TABLE 28 GLOBAL GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION)
TABLE 29 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 30 GLOBAL GENE THERAPY MARKET, FOR IN VIVO GENE THERAPY, BY REGION, 2019–2032 (USD MILLION)
TABLE 31 GLOBAL GENE THERAPY MARKET, FOR EX VIVO GENE THERAPY, BY REGION, 2019–2032 (USD MILLION)
TABLE 32 GLOBAL GENE THERAPY MARKET, BY REGION, 2019–2032 (USD MILLION)
TABLE 33 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 34 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 38 NORTH AMERICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 39 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 40 US: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 41 US: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 42 US: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 43 US: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 44 US: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 45 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 46 CANADA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 47 CANADA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 48 CANADA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 49 CANADA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 50 CANADA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 51 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 52 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 53 EUROPE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 54 EUROPE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 55 EUROPE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 56 EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 57 EUROPE: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 58 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 59 GERMANY: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 60 GERMANY: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 61 GERMANY: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 62 GERMANY: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 63 GERMANY: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 64 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 65 FRANCE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 66 FRANCE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 67 FRANCE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 68 FRANCE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 69 FRANCE: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 70 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 71 UK: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 72 UK: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 73 UK: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 74 UK: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 75 UK: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 76 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 77 ITALY: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 78 ITALY: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 79 ITALY: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 80 ITALY: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 81 ITALY: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 82 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 83 SPAIN: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 84 SPAIN: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 85 SPAIN: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 86 SPAIN: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 87 SPAIN: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 88 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 89 REST OF EUROPE: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 90 REST OF EUROPE: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 91 REST OF EUROPE: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 92 REST OF EUROPE: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 93 REST OF EUROPE: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 94 REST OF EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 95 ASIA-PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 96 ASIA-PACIFIC: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 97 ASIA-PACIFIC: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 98 ASIA-PACIFIC: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 99 ASIA-PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 100 ASIA-PACIFIC: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 101 ASIA-PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 102 CHINA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 103 CHINA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 104 CHINA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 105 CHINA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 106 CHINA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 107 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 108 INDIA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 109 INDIA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 110 INDIA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 111 INDIA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 112 INDIA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 113 INDIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 114 JAPAN: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 115 JAPAN: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 116 JAPAN: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 117 JAPAN: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 118 JAPAN: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 119 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 120 SOUTH KOREA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 121 SOUTH KOREA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 122 SOUTH KOREA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 123 SOUTH KOREA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 124 SOUTH KOREA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 125 SOUTH KOREA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 126 AUSTRALIA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 127 AUSTRALIA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 128 AUSTRALIA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 129 AUSTRALIA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 130 AUSTRALIA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 131 AUSTRALIA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 132 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 133 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 134 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 135 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 136 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 137 REST OF ASIA-PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 138 REST OF THE WORLD: GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)
TABLE 139 REST OF THE WORLD: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 140 REST OF THE WORLD: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 141 REST OF THE WORLD: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 142 REST OF THE WORLD: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 143 REST OF THE WORLD: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 144 REST OF THE WORLD: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 145 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 146 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 147 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 149 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 150 MIDDLE EAST & AFRICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 151 SOUTH AMERICA: GENE THERAPY MARKET, BY VECTOR TYPE, 2019–2032 (USD MILLION)
TABLE 152 SOUTH AMERICA: GENE THERAPY MARKET, FOR VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 153 SOUTH AMERICA: GENE THERAPY MARKET, FOR NON-VIRAL VECTOR, BY TYPE, 2019–2032 (USD MILLION)
TABLE 154 SOUTH AMERICA: GENE THERAPY MARKET, BY GENE TYPE, 2019–2032 (USD MILLION)
TABLE 155 SOUTH AMERICA: GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)
TABLE 156 SOUTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2019–2032 (USD MILLION)
TABLE 157 PUBLIC PLAYERS STOCK SUMMARY
TABLE 158 PRODUCT APROVAL/ PRODUCT LAUNCH
TABLE 159 ACQUISITION/ EXPANSION
TABLE 160 AGREEMENT/PARTNERSHIP/COLLABORATION
TABLE 161 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT OFFERED
TABLE 162 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS
TABLE 163 LONZA: PRODUCTS OFFERED
TABLE 164 LONZA: KEY DEVELOPMENTS
TABLE 165 UNIQURE N.V.: PRODUCTS OFFERED
TABLE 166 UNIQURE N.V.: KEY DEVELOPMENTS
TABLE 167 BLUEBIRD BIO, INC.: PRODUCTS OFFERED
TABLE 168 BLUEBIRD BIO, INC.: KEY DEVELOPMENTS
TABLE 169 ORCHARD THERAPEUTICS PLC: PRODUCTS OFFERED
TABLE 170 ORCHARD THERAPEUTICS PLC: KEY DEVELOPMENTS
TABLE 171 GENSIGHT BIOLOGICS: PRODUCTS OFFERED
TABLE 172 GENSIGHT BIOLOGICS: KEY DEVELOPMENTS
TABLE 173 NOVARTIS AG: PRODUCTS OFFERED
TABLE 174 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 175 AMGEN INC.: PRODUCTS OFFERED
TABLE 176 SAREPTA THERAPEUTICS INC.: PRODUCTS OFFERED
TABLE 177 SAREPTA THERAPEUTICS INC.: KEY DEVELOPMENTS
TABLE 178 SPARK THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 179 SPARK THERAPEUTICS, INC.: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 1 GLOBAL GENE THERAPY MARKET: STRUCTURE
FIGURE 2 GLOBAL GENE THERAPY MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENE THERAPY MARKET
FIGURE 6 GLOBAL GENE THERAPY MARKET, VECTOR TYPE SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2023 & 2032 (USD MILLION)
FIGURE 8 GLOBAL GENE THERAPY MARKET SHARE (%), BY VECTOR TYPE, 2023
FIGURE 9 GLOBAL GENE THERAPY MARKET, GENE TYPE SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 10 GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2023 & 2032 (USD MILLION)
FIGURE 11 GLOBAL GENE THERAPY MARKET SHARE (%), BY GENE TYPE, 2023
FIGURE 12 GLOBAL GENE THERAPY MARKET, APPLICATION SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 13 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)
FIGURE 14 GLOBAL GENE THERAPY MARKET SHARE (%), BY GENE TYPE, 2023
FIGURE 15 GLOBAL GENE THERAPY MARKET, DELIVERY METHOD SEGMENT, 2023 & 2032 (USD MILLION)
FIGURE 16 GLOBAL GENE THERAPY MARKET, BY DELIVERY METHOD, 2023 & 2032 (USD MILLION)
FIGURE 17 GLOBAL GENE THERAPY MARKET SHARE (%), BY DELIVERY METHOD, 2023
FIGURE 18 GLOBAL GENE THERAPY MARKET, BY REGION, 2023 & 2032 (USD MILLION)
FIGURE 19 GLOBAL GENE THERAPY MARKET SHARE (%), BY REGION, 2023
FIGURE 20 NORTH AMERICA MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2032
FIGURE 21 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 22 NORTH AMERICA: GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 23 EUROPE MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2032
FIGURE 24 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 25 EUROPE: GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 27 ASIA-PACIFIC: GENE THERAPY MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 28 ASIA-PACIFIC: GENE THERAPY MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: GENE THERAPY MARKET, 2019-2032 (USD MILLION)
FIGURE 30 REST OF THE WORLD: GENE THERAPY MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 31 REST OF THE WORLD: GENE THERAPY MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 32 GLOBAL GENE THERAPY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 33 COMPETITOR DASHBOARD: GLOBAL GENE THERAPY MARKET
FIGURE 34 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS
FIGURE 36 LONZA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 LONZA: SWOT ANALYSIS
FIGURE 38 UNIQURE N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 UNIQURE N.V.: SWOT ANALYSIS
FIGURE 40 BLUEBIRD BIO, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 GENSIGHT BIOLOGICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 NOVARTIS AG: SWOT ANALYSIS
FIGURE 44 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 AMGEN INC.: SWOT ANALYSIS
FIGURE 46 SAREPTA THERAPEUTICS INC.: FINANCIAL OVERVIEW SNAPSHOT
